Paper Chase is a research database designed to offer abstracts of research articles published in journals that have a highly rated impact factor as determined by ISI Impact Factor and PageRank. Abstracts are organized by date, with the most recently published papers listed first. 

Paper Chase

2.

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.

Lancet.
Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S, Sala J.
| Nov 10, 2017
3.

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Lancet.
Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S, Sala J.
| Nov 10, 2017
4.

Protect trans people: gender equality and equity in action.

Lancet.
Restar AJ, Reisner SL.
| Oct 28, 2017
5.

Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.

Lancet.
Prabhakaran D, Anand S, Watkins D, Gaziano T, Wu Y, Mbanya JC, Nugent R, Ajay VS.
| Nov 03, 2017
7.

Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the Lancet Commission report.

Lancet.
Knaul FM, Farmer PE, Krakauer EL, De Lima L, Bhadelia A, Jiang Kwete X, Arreola-Ornelas H, Gómez-Dantés O, Rodriguez NM, Alleyne GAO, Connor SR, Hunter DJ, Lohman D, Radbruch L, Del Rocío Sáenz Madrigal M, Atun R, Foley KM, Frenk J, Jamison DT, Rajagopal MR, Knaul FM.
| Oct 11, 2017
8.

Local, national, and regional viral haemorrhagic fever pandemic potential in Africa: a multistage analysis.

Lancet.
Pigott DM, Deshpande A, Letourneau I, Morozoff C, Reiner RC, Kraemer MUG, Brent SE, Bogoch II, Khan K, Biehl MH, Burstein R, Earl L, Fullman N, Messina JP, Mylne AQN, Moyes CL, Shearer FM, Bhatt S, Brady OJ, Gething PW, Weiss DJ, Tatem AJ, Caley L, De Groeve T, Vernaccini L, Golding N, Horby P, Kuhn JH, Laney SJ, Ng E, Piot P, Sankoh O, Murray CJL, Hay SI.
| Oct 11, 2017
9.

Tranexamic acid for post-partum haemorrhage in the WOMAN trial.

Lancet.
Miller S, Burke T, Belizán JM, Fuchtner C, Lalonde A, Malhorta J.
| Sep 30, 2017
10.

Physical activity lowers mortality and heart disease risks.

Lancet.
Goenka S, Lee IM.
| Sep 21, 2017
11.

Health professional education on trafficking: the facts matter.

Lancet.
Stoklosa H, Baldwin SB.
| Oct 07, 2017
12.

Antiangiogenesis to curb urothelial cancer.

Lancet.
Bellmunt J.
| Sep 12, 2017
13.

Transformational thinking about asthma.

Lancet.
Camargo CA.
| Sep 11, 2017
14.

Advances in paediatric urology.

Lancet.
Diamond DA, Chan IHY, Holland AJA, Kurtz MP, Nelson C, Estrada CR, Bauer S, Tam PKH.
| Sep 09, 2017
15.

Long-term implications and global impact of paediatric surgery.

Lancet.
Tam PKH, Davenport M, Chan IHY, Numanoglu A, Hoebeke P, Diamond DA.
| Sep 09, 2017
16.

What does endotyping mean for treatment in chronic obstructive pulmonary disease?

Lancet.
Agustí A, Celli B, Faner R.
| Sep 02, 2017
17.

Prevention of hearing loss in patients with multidrug-resistant tuberculosis.

Lancet.
Cox H, Reuter A, Furin J, Seddon J.
| Sep 02, 2017
18.

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.

Lancet.
Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E.
| Nov 04, 2017
19.

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

Lancet.
Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS.
| Oct 28, 2017

Search